...
首页> 外文期刊>Journal of Medical Genetics >A rapid, PCR based test for differential molecular diagnosis of Prader-Willi and Angelman syndromes.
【24h】

A rapid, PCR based test for differential molecular diagnosis of Prader-Willi and Angelman syndromes.

机译:一种基于PCR的快速测试,可对Prader-Willi和Angelman综合征进行分子鉴别。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Approximately 98% of Prader-Willi syndrome (PWS) and 80% of Angelman syndrome (AS) cases have deletions at a common region in chromosome 15q11-13, uniparental disomy for chromosomes 15 (UPD15), or mutations affecting gene expression in this region. The resulting clinical phenotype (PWS or AS) in each class of mutation depends upon the parent of origin. Both disorders are characterised at the molecular level by abnormal methylation of imprinted genes at 15q11-q13 including the small nuclear ribonucleoprotein N gene (SNRPN). Current diagnostic strategies include high resolution cytogenetics, fluorescence in situ hybridisation (FISH), Southern blot hybridisation, or microsatellite typing. We have developed a novel and rapid diagnostic test for PWS and AS based on differential digestion of expressed (paternally imprinted) SNRPN sequences by the methylation sensitive endonuclease NotI or repressed (maternally imprinted) SNRPN sequences by the methylation requiring nuclease McrBC, followed by PCR amplification of the SNRPN promoter. We have evaluated this test by blinded analysis of 60 characterised DNA samples (20 PWS, 20 AS, and 20 unaffected controls). SNRPN sequences could not be amplified from PWS patient DNA which had been digested with McrBC, nor from AS patient DNA which had been digested with NotI. We were able to make a correct diagnosis of PWS, AS, or unaffected in all 60 samples tested. This novel test is rapid and has a high specificity and sensitivity for deletion and UPD15 cases. These features make this new test suitable as the initial step in a molecular diagnostic strategy for PWS/AS.
机译:大约98%的Prader-Willi综合征(PWS)和80%的Angelman综合征(AS)病例在15q11-13号染色体的共同区域缺失,15号染色体的单亲二体性(UPD15)或影响该区域基因表达的突变。每种突变类型中产生的临床表型(PWS或AS)取决于来源的母体。在分子水平上,这两种疾病的特征是在15q11-q13时印迹基因的甲基化异常,包括小核糖核糖核蛋白N基因(SNRPN)。当前的诊断策略包括高分辨率细胞遗传学,荧光原位杂交(FISH),Southern印迹杂交或微卫星分型。我们已经基于甲基化敏感的核酸内切酶NotI对表达的(父标记的)SNRPN序列的差异消化或需要核酸酶的McrBC的甲基化对被抑制的(母标记的)SNRPN序列进行了差异消化,从而针对PWS和AS开发了新颖且快速的诊断测试SNRPN启动子。我们通过对60个特征化的DNA样品(20个PWS,20个AS和20个未受影响的对照)进行盲分析来评估该测试。不能从用McrBC消化过的PWS患者DNA或从用NotI消化过的AS患者DNA中扩增SNRPN序列。我们能够正确诊断PWS,AS或在所有60个样本中不受影响。这种新颖的检测速度很快,对缺失和UPD15病例具有很高的特异性和敏感性。这些功能使这项新测试适合作为PWS / AS分子诊断策略的第一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号